BMI, reproductive factors, and breast cancer molecular subtypes: A case-control study and meta-analysis

Hui Li a, Xuezheng Sun b, Erline Miller b, Qiong Wang a, c, Ping Tao d, Li Liu e, Ying Zhao a, Mengjie Wang a, Yana Qi a, d, Jiayuan Li a, *

a Department of Epidemiology and Biostatistics, West China School of Public Health, Sichuan University, Chengdu, China
b Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
c Department of Health Service Management, Public Health School, Sun Yat-Sen University, Guangzhou, Guangdong, China
d Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu, China
e The Comprehensive Guidance Center of Women’s Health, Chengdu Women’s and Children’s Central Hospital, Chengdu, China

A R T I C L E   I N F O
Article history:
Received 13 October 2015
Accepted 8 May 2016
Available online 9 December 2016

Keywords:
Breast cancer
East Asia
Body mass index
Reproductive factor
Molecular subtype

A B S T R A C T
Background: The effects of body mass index (BMI) and reproductive factors may vary among breast cancer molecular subtypes, evidence of which is lacking in East Asia.
Methods: From 2002 to 2010, 1256 breast cancer patients and 1416 healthy women were recruited. Anthropometric and reproductive factors were collected from medical charts. Breast cancer subtype was defined by ER, PR, and HER2 status. Polytomous logistic regression was used to evaluate associations between risk factors and breast cancer subtypes, with subgroup analysis by menopausal status. A meta-analysis of relevant published studies in East Asia was also performed.
Results: In our case-control study, late menarche was negatively associated with luminal tumor risk ($P_{trend} = 0.03$). Higher BMI was associated with risk of both luminal and triple-negative tumors ($P_{trend} < 0.001$). Late age at first live birth was associated with a 1.41- to 2.08-fold increased risk of all subtypes, while late menopause increased risk by 2.62–5.56 times. Heterogeneity of these associations was not detected for different menopausal statuses. The meta-analysis revealed a positive dose-response relationship between BMI and risk of both luminal and ER-PR- subtypes ($P_{trend} < 0.05$). Early menarche and nulliparity increased luminal tumor risk by 1.39 and 1.26 times, respectively. Non-breastfeeding also increased the risk of all subtypes.
Conclusions: For East Asian women, overweight, late menopause, and lack of breastfeeding appear to increase risk of both luminal and ER-PR- tumors. Early menarche and nulliparity mainly impacted luminal tumor risk. These associations were not impacted by menopausal status.

© 2016 The Authors. Publishing services by Elsevier B.V. on behalf of The Japan Epidemiological Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction
Breast cancer is the most common cancer among women worldwide, with an age-adjusted incidence of 43.3 cases per 100,000 people. Although the incidence of breast cancer is lower in East Asia compared with the West, there has been a rising trend in recent years, with an incidence in 2012 of 27.0 cases per 100,000 people.1

The heterogeneity of breast cancer has been widely recognized in the past decades. Subtypes include luminal, HER2-enriched, and basal-like types, based on global gene expression analyses.2 Breast cancer subtypes carry distinct clinicopathologic characteristics and prognoses, which suggests heterogeneous etiologies.3–5 Previous studies showed that women’s body size6 and reproductive factors, including early menarche, late menopause, nulliparity, late age at first live birth, and no lactation, had a relatively pronounced effect on elevating luminal tumor risk,6 while several recent studies have found a significant association between these factors and triple-negative tumors.6,11 However, the results of epidemiological studies have not been consistent.

Breast cancer risk factors are known to be distributed differently depending on menopausal status and race.12 Distribution differences in molecular subtypes among women of different menopausal status and ethnicity have also been demonstrated.
previously. Compared with white women, for example, East Asian women have a higher risk of triple-negative and HER2-enriched tumors. Luminal tumors are more commonly diagnosed among postmenopausal Caucasian women in Western countries, but conversely are more prevalent among premenopausal women in East Asia.

The difference in subtype distribution between white and black women has been extensively studied in Western countries, while little data are available for East Asian women, especially in China, where the incidence of breast cancer rose from 20.13 to 42.55 cases per 100,000 people from 2005 to 2009. The few Chinese studies that have been published reported inconsistent results for associations between common risk factors and different tumor subtypes, and these studies did not evaluate possible associations in groups of women with differing menopausal status. Furthermore, relevant studies from China were all conducted in the eastern part of the country, while China's western regions have disparate distributions of body size and reproductive factors due to varying levels of economic development.

Thus, we conducted this population-based case-control study in southwestern China to evaluate associations among BMI, reproductive factors, and breast tumor subtypes. Subgroup analysis was performed by menopausal status. We also conducted a meta-analysis to assess these associations among East Asian women. Our results supply some of the first data on these associations from less developed areas of China, and our meta-analysis is the first to pool the results of relevant studies in East Asia.

Methods

Study subjects

From 2002 to 2010 at Sichuan Cancer Hospital, 1256 pathologically and newly confirmed invasive breast cancer cases with molecular subtypes diagnosed in breast surgery were enrolled in the study. To form the control group, 1416 healthy women undergoing routine physical examinations during the same time period were randomly selected and frequency-matched to the cases by age. The controls were recruited at the Chengdu Children's and Women's Hospital, the leading institution providing medical treatment and health care for women and children in Sichuan Province, which supplies routine health examinations to women in the area. Controls with any known malignancy or mental disorder were excluded. The study protocol was approved by the institutional review boards of Sichuan University, Chengdu Children's and Women's Hospital, and Sichuan Cancer Hospital.

Data collection

Information on breast cancer risk factors was collected from the participants' medical records. Specifically, height and weight were measured, and information on other risk factors, including age at diagnosis, menopausal status, age at menarche, age at menopause, age at first live birth, parity, and breastfeeding were collected during interviews by trained nurses when the participants were admitted to the hospital for the first time or during the physical examination. Women who had lactated for at least 1 month were classed as "ever breastfed." A woman was defined as postmenopausal if she had undergone natural menopause (if she had experienced 12 continuous months without a menstrual cycle before any endocrine treatment or oophorectomy), bilateral oophorectomy, or irradiation of the ovaries before 50 years of age. If a woman was aged 50 or older and no longer experienced menstruation, she was also considered postmenopausal. BMI was calculated as body weight (kg)/height² (m²) and used as a measure of general obesity. The response rates for both cases and controls were 100%.

Biomarker detection

The ER, PR, and HER2 status of the patients was extracted from medical records. Tumor type was determined using immunohistochemical (IHC) assay at the pathology department of Sichuan Cancer Hospital. Positive ER and PR status was defined as ≥1% of tumor cells presenting positive nuclear staining. The results of HER2 were scored semi-quantitatively according to the estimated percentage of positively stained tumor cell nuclei and the intensity of nuclear staining (– for no staining, +1 for weak intensity, +2 for intermediate intensity, and +3 for strong intensity). Results of “−” or “+1” were classed as HER2 negative and “+3” as positive. A fluorescence in situ hybridization (FISH) test was recommended to “+2” patients to determine the HER2 expression status in the breast tumor. In our study, 20% of “+2” patients opted for the FISH test. Considering that less than 20% of women with “+2” were diagnosed as HER2 positive by FISH, we treated those who did not opt for FISH as HER2 negative.

All the patients were grouped into one of the following three categories: luminal (ER+/PR+, HER2−), HER2-enriched (ER−, PR−, HER2+), or triple-negative (ER−, PR−, HER2−).

Data analysis

BMI was categorized using the World Health Organization (WHO) definition of <18.5 kg/m² as underweight, 18.5–24.9 kg/m² as normal, 25–29.9 kg/m² as overweight, and ≥30 kg/m² as obese. We combined the overweight and obese groups due to the low proportion of obesity in the subjects (2%). Age at menarche and age at first live birth were divided into two categories according to common cutoff values reported previously. Due to the small number of nulliparous women (<5%), we did not include parity in the regression analysis. In the subgroup analysis performed according to menopausal status, all continuous variables were categorized into two levels due to the limited sample size in tumor subgroups. One-way analysis of variance and chi-square tests were used to compare the distribution of selected factors between controls and subgroups of cases. The distribution differences between groups were measured using trend chi-square tests. Polytomous logistic regression, which is suitable for multiple outcomes data, was used to evaluate the associations between BMI, reproductive factors, and risks for molecular subtypes. The weighted least square (WLS) method was used to test the heterogeneity of associations between risk factors and breast cancer subtypes. Data were analyzed with SPSS 17.0 software (IBM Corp, Armonk, NY, USA). All p-values were subjected to a two-tailed test, with an alpha level of 0.05 for significance testing.

Meta-analysis

Literature search

We searched for studies on the relationship between common factors and risk of breast cancer molecular subtypes among East Asian women in PubMed, Ovid, the Chinese Biomedical Literature Analysis and Retrieval System, and the Chinese National Knowledge Infrastructure for the period up to August 2015 using the following keyword combinations: (“risk factors” OR “reproductive factors” OR “body mass index”) AND (“breast cancer” OR “breast tumor” OR “breast malignancy”) AND (“subtypes” OR “hormonal status”) AND (“East Asia” OR “China” OR “Japan” OR “Korea” OR “Mongolia”). In addition, we checked the references of relevant papers for citations of similar studies. We included in our analysis studies with
molecular subtypes determined by joint ER/PR status or ER/PR/HER2 status. Only studies with sufficient data to estimate an odds ratio (OR) with 95% confidence interval (CI) were included. If multiple publications reported the same or overlapping data, the publication with the largest sample size or most recent publication was selected for inclusion.

Quality assessment

The Newcastle-Ottawa Quality Assessment Scale was used to assess the validity of the selected studies. Two of the items were not applicable for evaluating the included studies: (a) “structured interview where blind to case/control status”; and (b) “same method of ascertainment for cases and controls” (the invasive histopathological diagnostic procedure is unsuitable for healthy control subjects). Thus, a total of six criteria with seven scores were used in the quality assessment. A study that met six or seven criteria was ranked as “A”, a study that met four or five criteria was ranked “B”, and a study was ranked “C” if it met fewer than four criteria.

Data extraction

For each eligible study, the following information was extracted: the first author’s name, year of publication, country of origin, study design, menopausal status of cases, year subjects were recruited, sample size, tumor subtypes, matched factors, and adjusted confounding factors. The literature search, quality assessment, and data extraction were independently performed by two researchers. If divergence existed, they discussed with the third investigator and came to a final decision.

Statistical analysis

Pooled ORs and 95% CIs for the associations between BMI, reproductive factors, and breast cancer molecular subtypes were calculated via dividing the observed frequencies of categories by the unified cutoff values of eligible studies. Heterogeneity among the included articles was estimated by a chi-square-based Q-test. If significant heterogeneity was not detected (P > 0.05), the Mantel-Haenszel method was used to estimate the pooled OR and 95% CI. Otherwise, the DerSimonian and Laird method was selected. The WLS method was used to quantify the heterogeneity of associations between risk factors and breast cancer subtypes. Egger’s regression test was used to determine publication bias.23 Publication bias is considered to be present if the p-value of the intercept (a) is less than 0.05. Sensitivity analysis was performed via excluding the study with the largest weight and then evaluating the impact of the change on the pooled OR. Crude ORs with 95% CIs for each study, Q-tests, and pooled ORs with 95% CI were calculated using Review Manager 5.0 (Nordic Cochrane Center, Copenhagen, Denmark). The Egger’s and WLS tests were performed with SPSS 17.0. The p-values were subjected to a two-tailed test, with an alpha level of 0.05 for significance testing.

Results

The case-control study

Of the 1256 cases, 898 tumors (71.4%) were classified as luminal, 55(4.3%) as HER2-enriched, and 303/24.1% as triple-negative (Table 1). There was no statistical difference in average age, post-menopausal age, parity, or breastfeeding status among controls and the subtype groups (P > 0.05) (Table 1). The distribution of BMI, age at menarche, age at first live birth, and menopausal status varied among groups (P < 0.05) (Table 1).

Among all subjects, early age at menarche (<13 years old) increased the risk of luminal tumor compared with women who had undergone menarche at 15 years of age or older (ORluminal1.28; 95%CI, 0.99–1.67; Ptrend<0.05). The risk of luminal tumor rose along with increasing BMI (18.5–24.9 vs. <18.5: ORluminal1.58; 95%CI, 1.02–2.43; ≥25 vs. <18.5: ORluminal2.58; 95%CI, 1.60–4.14; Ptrend<0.001). A BMI of 25 kg/m² or more also increased triple-negative tumor risk (ORtriple-negative2.96; 95%CI, 1.34–6.54; Ptrend<0.001). Compared with women who had their first live birth when younger than 25 years old, those with later age at first live birth (25–29 years old) had an elevated risk of all subtypes (ORluminal1.41; 95%CI, 1.17–1.70; ORHER2-enriched2.08; 95%CI, 1.15–3.77; ORtriple-negative1.34; 95%CI, 1.02–1.76). The difference in associations between menarche age and the three subtypes of breast cancer was statistically significant (Pheterogeneity<0.05) (Table 2).

### Table 1

| Characteristics of breast cancer cases and controls. |
|-----------------------------------------|
| Risk factors  | Controls n = 1416 | Luminal n = 898 | HER2-enriched n = 55 | Triple-negative n = 303 | P-value$^b$ |
|------------|------------------|----------------|--------------------|----------------------|------------|
| Age, years | 47.96 (10.07) | 47.73 (10.93) | 48.62 (8.97) | 49.54 (10.74) | 0.06 |
| BMI, kg/m² | 22.32 (2.66) | 23.01 (2.88) | 22.65 (2.26) | 23.20 (3.03) | <0.001 |
| Age at menarche | 14.28 (1.68) | 14.27 (1.82) | 14.87 (1.78) | 14.49 (1.84) | 0.02 |
| Age at first live birth | 25.04 (2.64) | 24.50 (2.78) | 24.51 (2.50) | 24.18 (2.69) | <0.001 |
| Age at menopause | 48.98 (2.97) | 48.97 (4.29) | 49.24 (4.12) | 48.52 (4.35) | 0.44 |
| Menopause status | | | |
| No | 831 (58.8) | 554 (61.7) | 30 (54.5) | 154 (50.8) | 0.01 |
| Yes | 585 (41.2) | 344 (38.3) | 25 (45.5) | 149 (49.2) | |
| Parity | | | |
| 0 | 39 (2.8) | 28 (3.1) | 0 (0.0) | 15 (5.0) | 0.11 |
| ≥1 | 1377 (97.2) | 870 (96.9) | 55 (100.0) | 288 (95.0) | |
| Breastfeeding$^c$ | | | |
| No | 95 (6.9) | 40 (5.6) | 5 (9.1) | 21 (7.3) | 0.51 |
| Yes | 1282 (93.1) | 821 (94.4) | 50 (90.9) | 267 (92.7) | |
| Family history of breast cancer | | | |
| No | 1391 (98.2) | 860 (95.8) | 54 (98.2) | 290 (95.7) | 0.002 |
| Yes | 25 (1.8) | 38 (4.2) | 1 (1.8) | 13 (4.3) | |

BMI, body mass index.

$^a$ Mean (standard deviation); age, BMI, age at menarche, age at first live birth, age at menopause. n (%): menopause status, parity, breastfeeding, tumor subtype, family history of breast cancer.

$^b$ One-way analysis of variance: age, BMI, age at menarche, age at first live birth, age at menopause; Chi-square test: menopause status; Fisher’s exact test: parity, breastfeeding, family history of breast cancer.

$^c$ Among parous women.
In premenopausal women, higher BMI (≥25 kg/m²) was associated with elevated risk of luminal and triple-negative subtypes (ORluminal1.88; 95%CI, 1.31–2.69; ORtriple-negative2.51; 95%CI, 1.53–4.12), and late age at first live birth (≥25 years old) was linked with increased risk of luminal tumor (ORluminal1.39; 95%CI, 1.10–1.76) (Table 3). In postmenopausal women, overweight and obesity (BMI ≥ 25 kg/m²) was associated with an increased risk of the luminal subtype only (ORluminal1.48; 95%CI, 1.08–2.04). Increased age at first live birth (≥25 years) was associated with elevated risk of luminal tumor (ORluminal1.41; 95%CI, 1.04–1.90), and women with older menopausal age (≥55 years old) had higher risk of all subtypes (ORluminal1.11; 95%CI, 1.61–6.02; ORHER2-enriched5.56; 95%CI, 1.41–21.93; ORtriple-negative4.65; 95%CI, 1.12–3.33). In postmenopausal women, the associations between age at menarche and tumor subtypes still showed significant heterogeneity (P = 0.05) (Table 3).

**Meta-analysis**

Among the 259 retrieved studies, 176 studies were irrelevant, 12 were case series studies, 49 focused on genetic and other environmental factors, and the outcome of 10 studies was survival status. Of the remaining 12 studies, the risk factors in Yoo’s,24 Suzuki’s,25 and Tamaki’s26 studies from Japan, Chung’s study from Korea,27 and Adam’s study from China28 lacked frequencies, and one study including subjects from Vietnam and China reported the molecular subtypes according to single ER status, PR status, or HER2 status.29 Among the remaining six studies,18,19,30–32 two studies from Japan were performed on an overlapping data set. In considering whether it was feasible to pool the data, we used the frequencies of BMI from Sueta et al33 and that of reproductive factors reported by Islam30 to calculate pooled effects separately. The flow diagram of the study selection is shown in Fig. 1.

Among the six included studies, two were ranked as “A” and four were ranked as “B” quality. Two studies were from China and four were from Japan (Table 4). Few studies were eligible to be included in the pooled analysis according to menopausal status, so we only conducted the meta-analysis in controls. Thus, a total of 8,637 cases and 13,001 controls (including those from our own case-control study) were included in the final analysis. The categories of menopausal age and age at menarche in our own case-control study were re-divided to be consistent with the majority of the selected studies. The breast tumor molecular subtypes were classified as luminal (ER+/PR+), and ER−PR−. When possible, the latter was further divided into two groups: HER2-enriched and triple-negative.

Compared with women with a BMI of less than 18.5 kg/m², those with a BMI of between 18.5 kg/m² and 24.9 kg/m² had marginally increased risk of both luminal (ORluminal1.20; 95%CI, 0.96–1.49) and ER−PR− tumors (ORER−.PR−1.43; 95%CI, 1.00–2.05). A BMI of more than 25 kg/m² conferred higher risks of both subtypes (ORluminal1.75; 95%CI, 1.30–2.35 and ORER−.PR−1.95; 95%CI, 1.04–3.65). Women who experienced menopause after 50 years of age also had increased risk of luminal and ER−PR− tumors (ORluminal1.15; 95%CI, 1.00–1.32 and ORER−.PR−1.19; 95%CI, 1.00–1.43). Younger age at menarche (<12 years old) (ORluminal1.39; 95%CI, 1.23–1.57) and nulliparity (ORluminal1.26; 95%CI, 1.11–1.44) only increased the risk of luminal tumor. Lack of breastfeeding history increased the risk of all the molecular subtypes (ORluminal1.35; 95%CI, 1.05–1.74; ORHER2-enriched1.97; 95%CI, 1.39–2.80; and ORtriple-negative1.85; 95%CI, 1.06–3.21). The differences in associations between age at menarche, parity, age at first live birth, breastfeeding, and breast tumor subtypes were significant (all P heterogeneity <0.05) (Table 5). After removing the study with the largest weight, the significant associations between menopausal age and luminal tumor risk and between breastfeeding and triple-negative tumor...
The magnitude of the associations observed in these studies was similar to that observed in the present study. We also found that overweight and obesity were associated with increased premenopausal risk of both luminal and triple-negative tumors. For triple-negative tumors, a meta-analysis of case-control studies found that obesity was associated with an increased triple-negative tumor risk among premenopausal women (OR:1.43; 95% CI, 1.23–1.65), which was similar to our results. For luminal subtypes, Yang’s meta-analysis, which included 12 population-based American studies, found a 1.36-times higher risk of premenopausal luminal tumors for those with higher BMI. However, the EPIC study and the case-control study from Japan reported a small inverse association between BMI and premenopausal luminal tumors (HRs and ORs ranged from 0.79 to 0.93, with 95% CIs excluding 1), while the Shanghai study found no significant association. Differing prevalence of obesity and subtypes in different populations may contribute to the disparity of these results.

An experimental study found that obesity was positively correlated with levels of leptin, the addition of which increased cell proliferation in ER-positive breast cancer cell lines. And an experiment using the C3(1)T6a murine model demonstrated that weight loss could prevent basal-like breast cancer by blocking the obesity-responsive pro-tumorogenic hepatocyte growth factor/c-Met pathway. Thus, theoretically, obesity may increase both luminal and triple-negative tumor risk in premenopausal and
postmenopausal women. Accordingly, the heterogeneous results for the effects of BMI on breast tumor subtypes were not significant in our case-control study and meta-analysis. The mechanism of obesity’s impact on tumor risk in women of different menopausal statuses merits further study. Based on our results, it could be deduced that, although the rate of obesity is relatively low for Chinese women (5.6%), premenopausal women may be relatively sensitive to obesity as a risk factor for breast cancer. Our results highlight the importance of weight control in premenopausal women.

Early age at menarche and delayed menopause may prolong the exposure period of estrogen and enhance breast cancer risk. Our case-control study found that, of these two factors, only early menarche was associated with luminal tumor risk, a relationship also found in our subsequent meta-analysis in East Asians. This finding also accords with Yang’s meta-analysis of 12 population-

![Flow diagram of the study selection](image)

**Fig. 1.** The flow diagram of the study selection.

**Table 4** Characteristics of included studies in meta-analysis.

| First author (published year) | Region | Menopausal status | Study design | Year subjects were recruited | Sample size, case/control | Type of tumor | Risk factors | Matched factor | Adjusted factors | Rank (Number of qualified items) |
|------------------------------|--------|-------------------|--------------|-------------------------------|---------------------------|---------------|-------------|---------------|----------------|---------------------------------|
| Bao et al. 2011              | China  | total/pre/post    | PCC          | 1996–1998/2002–2005           | 2676/3474                 | ER+, PR+, ER−, PR−, ER−/PR−, Luminal, HER2-enriched, TN | B,C,D,E,F | age                          | Age, menopausal status | A (6) |
| Islam et al. 2012            | Japan  | total             | HCC          | 2003–2005                     | 706/1412                  | ER+, PR+, ER−, PR−, Luminal, HER2-enriched, TN | B,C,D,E,F | age                          | Age, menopausal status | B (5) |
| Sueta et al. 2012            | Japan  | total/pre/post    | HCC          | 2001–2005                     | 715/1430                  | Luminal, HER2-enriched, TN | A            | Age                          | Menopausal status | B (5) |
| Kawai et al. 2012            | Japan  | total             | HCC          | 1997–2009                     | 1092/3160                 | ER+, PR+, ER−/PR−, ER−/PR−, Luminal, HER2-enriched, TN | A,B,C,D,E,F | Age                          | Age, menopausal status | B (5) |
| Miyagawa et al. 2013         | Japan  | total/pre/post    | PCC          | 2005–2012                     | 615/682                   | Luminal A, Luminal B, HER2-enriched, TN | C            | –                           | –                          | B (5) |
| Xing et al. 2009             | China  | total             | PCC          | 2001–2009                     | 1417/1587                 | Luminal A, Luminal B, HER2-enriched, TN | B,C,D,E,F | Age                          | Age, menopausal status | B (4) |
| Present study                | China  | total/pre/post    | PCC          | 2002–2012                     | 1416/1256                 | Luminal A, Luminal B, HER2-enriched, TN | A,B,C,D,E,F | Age                          | Age, menopausal status | – |

*ER, estrogen receptor; HCC, hospital-based case-control study; PCC, population-based case-control study; PR, progesterone receptor; TN, triple-negative.

a Risk factors included in this meta-analysis: A. BMI B. age at menarche C. parity D. age at first live birth E. breastfeeding F. menopausal age.

b Risk factors adjusted for in the studies: 1. age, 2. education, 3. history of breast fibroadenoma, 4. family history of breast cancer, 5. physical exercise, 6. BMI, 7. waist-to-hip ratio, 8. history of live birth, 9. parity, 10. study phase, 11. years of menstruation, 12. age at menarche, 13. menopausal status, 14. age at first live birth, 15. hormone use, 16. referral pattern, 17. smoking, 18. alcohol use, 19. occupation, 20. year of recruitment, 21. area of residence, 22. age at menopause, 23. induced abortion, 24. spontaneous abortion, 25. history of hysterectomy, and 26. breastfeeding.

* Results of quality assessment and number of qualified items according to the Newcastle-Ottawa Quality Assessment Scale (NOS) for case-control studies.
Table 5

| Risk factors | Nstudy | Ncontrol | HER2-enriched | Triple-negative | Pooled OR (95% CI) |
|--------------|--------|----------|---------------|-----------------|------------------|
| BMI, kg/m²   |        |          |               |                 |                  |
| <18.5        | 3      | 415      | 110           | 1.00            |                  |
| 18.5–24.9    | 3      | 410      | 1432          | 1.00 (1.06–1.48)| 0.68             |
| 25–29.9      | 3      | 1349     | 534           | 1.00 (1.06–1.48)| 0.07             |
| ≥30.0        | 3      | 1363     | 682           | 1.00 (1.06–1.48)| 0.07             |
| Menopausal age, years |        |          |               |                 |                  |
| <25          | 3      | 360      | 109           | 1.00            |                  |
| 25–50        | 3      | 359      | 119 (1.00–1.43)| 0.06            | 0.32             |
| ≥50          | 3      | 948      | 1.00 (1.06–1.48)| 0.11            | 0.01             |
| Age at menarche, years |        |          |               |                 |                  |
| <12          | 4      | 4694     | 364           | 1.00            |                  |
| 12–18        | 5      | 406      | 282           | 1.00 (1.06–1.48)| 0.28             |
| ≥19          | 3      | 505      | 282           | 1.00 (1.06–1.48)| 0.28             |
| Age at first live birth, years |        |          |               |                 |                  |
| <18          | 3      | 624      | 109           | 1.00            |                  |
| 18–24        | 3      | 1092     | 534           | 1.00 (1.06–1.48)| 0.07             |
| ≥25          | 3      | 1593     | 682           | 1.00 (1.06–1.48)| 0.07             |
| Breastfeeding |      |          |               |                 |                  |
| Yes          | 3      | 412      | 109           | 1.00            |                  |
| No           | 3      | 624      | 109           | 1.00 (1.06–1.48)| 0.07             |

a P-values (two-sided) were based on a Q-test of heterogeneity between included studies.

b PH2: P-value of heterogeneity of exposure-disease ORs among luminal, HER2-enriched and triple-negative subtypes.

c PH1: P-value of heterogeneity of exposure-disease ORs among HER2-enriched and triple-negative subtypes.

d P-value for trends calculated by trend chi-square.

e The pooled odds ratio was calculated by a random-effects model.

Breastfeeding may increase the protective effect of pregnancy by inducing terminal differentiation, removal of initiated breast epithelial cells, excretion of carcinogenic agents, and delay in ovulation.49 In the present case-control study, we found no association between breastfeeding and any breast cancer molecular subtype in total, pre-, or postmenopausal women. However, the meta-analysis demonstrated that lack of breastfeeding increased the risk of all breast cancer subtypes, and the effect of non-breastfeeding on ER–PR– tumor risk was significantly stronger than that on risk of the luminal subtype. This accords with Ma’s meta-analysis48 and Anderson’s recent systematic review.11 Our results indicate that age at first delivery and breastfeeding may affect breast cancer risk via several mechanisms.
With increasing economic prosperity, more East Asian women exercise reproductive control. In China, for example, between 1982 and 2001, the proportion of women whose first live birth occurred at 30 years of age or older increased from 1.35% to 4.86%.50 and the prevalence of non-lactation in premenopausal women increased from 9.5% to 22.7% from births in 1950 to 1970.13 This information, combined with our results, suggests the role of health education in childbearing choices and the need to encourage breastfeeding for young Chinese mothers.

This case-control study has several limitations. First, some of the subsets of interest were limited in sample size, and other population-based studies are needed to replicate the results. Second, only 20% of “+2” patients were FISH-tested, so a non-differential bias may exist. Considering that fewer than 20% of women with “+2” were diagnosed as HER2-positive using FISH, the non-differential bias may be small. Third, in this study, we included common risk factors that were previously hypothesized to affect peripheral estrogen levels. Although we adjusted for the most important known risk factors (age and family history of breast cancer) for breast cancer, several other well-known risk factors for breast cancer were not included. Further study including other well-known risk factors is needed to verify our results. In addition, we measured BMI when patients were admitted to the hospital for the first time. Since their body weight might be changed by presence of breast cancer, the observed associations might be due to reverse causality, and our study design did not allow us to make definitive causal inferences.

Sichuan Cancer Hospital is the leading tertiary hospital providing diagnosis, treatment, and routine follow-up care for patients with breast cancer in Sichuan Province, and Chengdu Children’s and Women’s Hospital is the leading tertiary institution providing health care for women and children in Sichuan Province. In Sichuan Cancer Hospital, more than 70% of patients came from Chengdu and areas within a radius of <150 km, and the controls were community women who attended routine physical examinations in Chengdu or suburban areas nearby. Thus, we believe that most women in the control group would go to Sichuan Cancer Hospital if they had breast cancer, so the controls represent the source population of cases to a certain degree. Our results in this case-controls study may be specific to Chengdu. In order to better observe the association between BMI, reproductive factors, and breast cancer subtypes, we conducted a meta-analysis in East Asia women. The results of studies included in the meta-analysis were homogenous, and the effects for most of the risk factors were stable. Thus, we believe the results of meta-analysis were acceptable.

In summary, for East Asian women, overweight, late menopause, and lack of breastfeeding appear to increase risks of both luminal and ER–PR– tumors. Early menarche and nulliparity may contribute chiefly to the risk of luminal tumor. In our study, these associations were not impacted by menopausal status. Most of these findings were similar to those in studies conducted in Western countries. In addition, late age at first live birth may increase the risk of luminal tumor, which needs to be evaluated further in a larger East Asian population.

Conflicts of interest
None declared.

Acknowledgements
This work was supported by NO. 81302500 from the National Natural Science Foundation of China. We thank Shawna Williams for editing this article.

Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.je.2016.05.002.

References
1. Ferlay JSI, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globo-canarc.fr, accessed on day/month/year. 2012;Available from: http://globocan.iarc.fr, Accessed on day/month/year.
2. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 1999;5.0:593–602.
3. Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst 2014:106.
4. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 2006:37:1217–1226.
5. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005:11:5678–5685.
6. Haque R, Ahmed SA, Inzhakova G, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012: 1848–1855.
7. Shim HJ, Kim SH, Kang BJ, et al. Breast cancer recurrence according to molecular subtype. Asian Pac J Cancer Prev. 2014:15:5339–5344.
8. Kongsiang T, Tangvoraphonkhai V, Jirapornkul C, Promthep S, Kamsa-Ard S, Suwanrungruang K. Survival time and molecular subtypes of breast cancer after radiotherapy in Thailand. Asian Pac J Cancer Prev. 2014:15:10505–10508.
9. Amadou A, Hainaut P, Romieu I. Role of obesity in the risk of breast cancer: lessons from anthropometry. J Oncol. 2013:2013:906495.
10. Anderson KN, Schweb B, Martinez ME. Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat. 2014:144:1–16.
11. Parsa P, Parsa B. Effects of reproductive factors on risk of breast cancer: a literature review. Asian Pac J Cancer Prev. 2009:10:3545–3550.
12. Lee H, Li JY, Fan JH, et al. Risk factors for breast cancer among Chinese women: a 10-year nationwide multicenter cross-sectional study. J Epidemiol. 2014:24:67–76.
13. Clarke CA, Keegan TH, Yang J, et al. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 2014:106:1094–1101.
14. Song Q, Huang R, Li J, et al. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multicenter study in China. PloS One. 2013:8:e72175.
15. Zhao P, Cancer incidence and Mortality in Chinese cancer registration Areas in 2005. Beijing: Medical Military Science Press; 2008.
16. Hao J CW, Beijing: Military Medical Science Press; 2012.
17. Bao PP, Shu XO, Gao YT, et al. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the Shanghai breast cancer study. Am J Epidemiol. 2011:174:661–671.
18. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol. 2010:27:928–931.
19. Zheng S, Bai JQ, Li J, et al. The pathologic characteristics of breast cancer in China and its shift during 1999-2008: a national-wide multicenter cross-sectional image over 10 years. Int J Cancer. 2012:131:2622–2631.
20. Peng A, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008:17:2078–2086.
21. Perry CSOJ, Palmer JL, Gross AS. Risk factors for breast cancer in East Asian women relative to women in the West. Asia Pac J Clin Oncol. 2009:5:219–231.
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997:315:629–634.
23. Yoo KY, Tajima K, Miwa S, et al. Breast cancer risk factors according to combined estrogen and progesterone receptor status: a case-control analysis. Am J Epidemiol. 1997:146:307–314.
24. Suzuki R, lwasaki M, Inoue M, et al. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status—the Japan public health center-based prospective study. Int J Cancer. 2011:129:1214–1224.
25. Tamaki K, Tamaki N, Terukina S, et al. The correlation between body mass index and breast cancer risk or estrogen receptor status in Okinawan women. Tohoku J Exp Med. 2014:234:169–174.
38. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancer. *Breast Cancer Res Treat*. 2006;15:1170–1178.

39. Nichols HB, Tretham-Dietz A, Love RR, et al. Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. *Cancer Epidemiol Biomarkers Prev*. 2005;14:41–47.

40. Islam T, Matsuo K, Ito H, et al. Reproductive and hormonal risk factors for luminal, HER2-overexpressing, and triple-negative breast cancer in Japanese women. *Ann Oncol*. 2012;23:2435–2441.

41. Kawai M, Kakugawa Y, Nishino Y, Hamanaka Y, Ohuchi N, Minami Y. Reproductive factors and breast cancer risk in relation to hormone receptor and menopausal status in Japanese women. *Sci Cancer*. 2012;103:1861–1870.

42. Miyagawa Y, Miyake T, Yanai A, et al. Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women. *Breast Cancer*. 2015;22:399–405.

43. Sueta A, Ito H, Islam T, et al. Differential impact of body mass index and its change on the risk of breast cancer by molecular subtype: a case-control study in Japanese women. *Springerplus*. 2012;1:39.

44. Arcidiacono B, Iritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. *Exp Diabetes Res*. 2012;2012:789174.

45. Canchola AJ, Anton-Culver H, Bernstein L, et al. Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. *Cancer Causes Control*. 2012 [Epub ahead of print].

46. Phipps AI, Buist DS, Malone KE, et al. Breast density, body mass index, and risk of tumor marker-defined subtypes of breast cancer. *Ann Epidemiol*. 2012;22:340–348.

47. Ritte R, Lukanova A, Berrino F, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. *Breast Cancer Res*. 2012;14:R76.

48. Pierobon M, Franklinfeld CL. Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. *Breast Cancer Res Treat*. 2013;137:307–314.

49. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *J Natl Cancer Inst*. 2011;103:250–263.

50. Rose DP, Vona-Davis L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. *Biol Factors*. 2014;40:1–12.

51. Sundaram S, Le TL, Essaid L, et al. Weight loss reversed obesity-induced HGF/c-met pathway and basal-like breast cancer progression. *Front Oncol*. 2014;4:175.

52. Li LM, Rao KQ, Kong LZ, et al. A description on the Chinese national nutrition and health survey in 2002. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2005;26:478–484.

53. Tamimi RM, Colditz GA, Hazra A, et al. Traditional breast cancer risk factors in relation to molecular subtypes of breast cancer. *Breast Cancer Res Treat*. 2012;131:159–167.

54. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. *Cancer Epidemiol Biomarkers Prev*. 2004;13:1558–1568.

55. Horn J, Opdahl S, Engstrom MJ, et al. Reproductive history and the risk of molecular breast cancer subtypes in a prospective study of Norwegian women. *Cancer Causes Control*. 2014;25:881–889.

56. Li CL, Malone KE, Daling JR, et al. Timing of menarche and first full-term birth in relation to breast cancer risk. *Am J Epidemiol*. 2008;167:230–239.

57. Ma H, Wang Y, Sullivan-Halley J, et al. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women’s contraceptive and reproductive experiences study. *Cancer Res*. 2010;70:575–587.

58. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. *Breast Cancer Res*. 2006;8:R43.

59. Russo J, Balogh GA, Heulings R, et al. Molecular basis of pregnancy-induced breast cancer protection. *Eur J Cancer Prev*. 2006;15:306–342.

60. Li L, Ji J, Wang JB, Niyazi M, Qiao YL, Boffetta P. Attributable causes of breast cancer and ovarian cancer in China: reproductive factors, oral contraceptives and hormone replacement therapy. *Chin J Cancer Res*. 2012;24:9–17.